Lundbeck Ready To File Alzheimer’s Agitation Treatment, A Potential First
Filing Expected In Q4
Executive Summary
Brexpiprazole could be approved as soon as 2023, and Lundbeck has pledged to support its uptake with investment in its salesforce and direct-to-consumer advertising.